-
Morgan Stanley Downs AUXL To Equal Weight
Friday, March 18, 2011 - 6:53am | 58Analysts at Morgan Stanley downgrade Auxilium Pharmaceuticals Inc (NASDAQ: AUXL) from “overweight” to “equal weight.” The target price for AUXL has been lowered from $34 to $26. AUXL shares gained 1.41% to close at $23.00 yesterday. More Analyst Ratings here
-
Buyers Step Back In 03-17-2011
Thursday, March 17, 2011 - 6:37pm | 877Cusick's Corner Buyers stepped back in today after a three day slide. Strong economic reports helped boost moods on Wall Street, temporarily putting aside fears over Japan's crisis. Heavy trading in the iShares Japan ETF (EWJ) continued for another day (see ETF Trading). The CBOE Volatility...
-
Lilly Announces Important Action Regarding Recall of Alcohol Prep Pads Made by Triad Group
Thursday, March 17, 2011 - 4:16pm | 194Eli Lilly and Company (NYSE: LLY) announced today that patients should not use the alcohol prep pads made by the Triad Group that are contained in the black starter kits for Forteo [teriparatide (rDNA origin) injection] in the United States. The Triad Group is recalling the alcohol prep pads due...
-
Zings Of The Day (PFE, V, KO, PEP)
Thursday, March 17, 2011 - 3:59pm | 185Just a couple of weeks after Pfizer (NYSE: PFE) completed the buy of King Pharmaceuticals, it has to recall a painkiller because of formulation problems. With these headaches, Pfizer better hope it has some laying around to help ease the pain. Visa (NYSE: V) announced yesterday that it is working...
-
Options Brief: Jazz Pharmaceuticals (JAZZ)
Thursday, March 17, 2011 - 3:38pm | 84Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) are lower on the session by 0.56%, trading at $28.51. Overall put volume is now running at 14.00x the daily average, with 58% of all puts traded being purchases on the offer. 3,793 contracts have traded on the session so far. Jazz Pharmaceuticals,...
-
Biotech/Pharma Sector Close-Up; Drug Resistance Potential for HIV Drugs; Can Medical Devices take over when drugs fail?
Thursday, March 17, 2011 - 2:22pm | 1780Point Roberts, WA - March 18, 2011 - Investorideas.com, a leader in investor sector research including biotech and pharma stocks releases a sector snapshot on the HIV- AIDS drug makers and recent data that suggests the HIV virus may be following the path of bacteria that has developed drug...
-
Options Brief: Mylan Inc. (MYL)
Thursday, March 17, 2011 - 1:39pm | 83Shares of Mylan Inc. (NASDAQ: MYL) are higher on the session by 1.32%, trading at $21.42. Overall call volume is now running at 2.08x the daily average, with 66% of all calls traded being purchases on the offer. 3,333 contracts have traded on the session so far. Mylan Inc. is a global...
-
CPEX Pharmaceuticals Advises Stockholders to Take No Action in Response to Mangrove Partners' Revised Proposal
Thursday, March 17, 2011 - 9:22am | 131CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today confirmed that it has received an unsolicited, non-binding letter from Mangrove Partners revising the terms of the potential alternative transaction involving a recapitalization of CPEX that Mangrove had initially proposed on March 14, 2011. CPEX...
-
Should You Add A Joint To Your Portfolio? (MJNA, VRX)
Thursday, March 17, 2011 - 8:56am | 518As some U.S. states have migrated toward the legalization of marijuana, most have failed to appreciate the potential economic and societal benefits that this legislature would provide. As Benzinga readers were informed already, over 500 economists signed a letter to governmental bodies citing the...
-
Allergan To Discuss Phase III Data On Botox 3/22
Thursday, March 17, 2011 - 8:51am | 117Morgan Stanley has published a research report on Allergan Inc. (NYSE: AGN) in anticipation of the company's Botox bladder expert call scheduled for March 22nd. In the report, Morgan Stanley writes "We are hosting Dr. Michael Chancellor at 9AM on Tuesday, March 22, to discuss the first Phase III...
-
Jefferies Raises PT On COR To $18
Thursday, March 17, 2011 - 8:08am | 86Jefferies has issued a report raising the Price Target of CoreSite Realty (NYSE: COR) from $17.00 to $18.00. According to the report, "2011 FFO/sh guidance of $1.00 to $1.12 vs. pre-earnings consensus at $0.99 reflects the strong underlying multi-year growth story at COR. We expect 10%+ annual FFO...
-
Piper Jaffray Overweight On Watson Pharmaceuticals (WPI)
Thursday, March 17, 2011 - 8:03am | 200Piper Jaffray has an Overweight rating and a $62 price target on shares of Watson Pharmaceuticals (NYSE: WPI). In a note to clients, Piper Jaffray writes, "Yesterday, we hosted a conference call with Dr. Celeste Durnwald, a maternal andfetal medicine (MFM) specialist, who was also an investigator...
-
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
Thursday, March 17, 2011 - 7:38am | 123ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it has elected to exercise its option with Merck & Co., Inc. (NYSE: MRK), to co-promote ridaforolimus, an investigational mTOR inhibitor, in the sarcoma indication upon its potential approval in the United States next year. Based...
-
Jefferies Raises PT On CoreSite Realty Corporation To $18
Thursday, March 17, 2011 - 7:21am | 29Jefferies has raised the price target on CoreSite Realty Corporation (NYSE: COR) from $17.00 to $18.00 and maintains its Buy rating.
-
Top 4 Large-Cap Stocks In The Healthcare Sector With The Lowest PEG Ratio (CELG, TEVA, GILD, GENZ)
Thursday, March 17, 2011 - 2:29am | 130Below are the top large-cap healthcare stocks on the NYSE and the NASDAQ in terms of PEG ratio Celgene Corporation (NASDAQ: CELG) has a PEG ratio of 0.63. CELG's trailing-twelve-month operating margin is 32.20%. Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) has a PEG ratio of 0.67. TEVA's...